Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Receivables - Other: 2014-2023

Historic Receivables - Other for Fortress Biotech (FBIO) over the last 7 years, with Dec 2023 value amounting to $100,000.

  • Fortress Biotech's Receivables - Other fell 94.74% to $100,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $100,000, marking a year-over-year decrease of 94.74%. This contributed to the annual value of $100,000 for FY2023, which is 94.74% down from last year.
  • Latest data reveals that Fortress Biotech reported Receivables - Other of $100,000 as of Q4 2023, which was down 66.67% from $300,000 recorded in Q1 2023.
  • Over the past 5 years, Fortress Biotech's Receivables - Other peaked at $1.9 million during Q4 2022, and registered a low of $100,000 during Q2 2022.
  • For the 3-year period, Fortress Biotech's Receivables - Other averaged around $633,333, with its median value being $400,000 (2021).
  • Per our database at Business Quant, Fortress Biotech's Receivables - Other surged by 146.91% in 2019 and then crashed by 94.74% in 2023.
  • Fortress Biotech's Receivables - Other (Quarterly) stood at $1.4 million in 2019, then rose by 14.29% to $1.6 million in 2020, then remained steady at $1.6 million in 2021, then climbed by 18.75% to $1.9 million in 2022, then tumbled by 94.74% to $100,000 in 2023.
  • Its last three reported values are $100,000 in Q4 2023, $300,000 for Q1 2023, and $1.9 million during Q4 2022.